We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-4.07%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.61B
AUM Growth
-$1.09B
Cap. Flow
-$352M
Cap. Flow %
-4.08%
Top 10 Hldgs %
30.78%
Holding
207
New
16
Increased
51
Reduced
80
Closed
30

Top Buys

Rank Stock Value
1
OM icon
Outset Medical
OM
+$58.4M
2
BSX icon
Boston Scientific
BSX
+$41.2M
3
PACB icon
Pacific Biosciences
PACB
+$38.3M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$37.2M
5
CDNA icon
CareDx
CDNA
+$32.9M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$109M
2
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
+$75.3M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$73.9M
4
DHR icon
Danaher
DHR
+$66.3M
5
HUM icon
Humana
HUM
+$65.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.39%
2 Industrials 0.69%
3 Energy 0.03%
4 Technology 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACCD
51
DELISTED
Accolade Inc
ACCD
$59.4M 0.69%
3,381,507
+660,132
+24% +$12.1M
CRSP icon
52
CRISPR Therapeutics
CRSP
$4.63B
$58.2M 0.68%
926,905
-47,779
-5% -$3M
APLS
53
DELISTED
Apellis Pharmaceuticals
APLS
$55.8M 0.65%
1,098,712
+448,121
+69% +$19.8M
CNC icon
54
Centene
CNC
$32.5B
$55.6M 0.65%
660,635
+625
+0.1% +$51.3K
GMED icon
55
Globus Medical
GMED
$10.3B
$55M 0.64%
745,254
-12,210
-2% -$849K
ABBV icon
56
AbbVie
ABBV
$448B
$50.5M 0.59%
311,500
+4,600
+1% +$668K
EXAS
57
DELISTED
Exact Sciences
EXAS
$50.3M 0.58%
719,303
+76,721
+12% +$5.61M
ABMD
58
DELISTED
Abiomed Inc
ABMD
$49.7M 0.58%
150,178
– –
OMCL icon
59
Omnicell
OMCL
$2.06B
$46.9M 0.54%
362,332
– –
BMY icon
60
Bristol-Myers Squibb
BMY
$123B
$45.9M 0.53%
628,128
-431,219
-41% -$29M
PACB icon
61
Pacific Biosciences
PACB
$422M
$44.4M 0.52%
4,881,752
+3,328,729
+214% +$38.3M
ADPT icon
62
Adaptive Biotechnologies
ADPT
$3.5B
$43.7M 0.51%
3,145,293
+1,176,862
+60% +$18.5M
SILK
63
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$43.2M 0.5%
1,045,567
+93,134
+10% +$3.28M
PEN icon
64
Penumbra
PEN
$12.5B
$43M 0.5%
193,654
-80
-0% -$17.8K
TMO icon
65
Thermo Fisher Scientific
TMO
$196B
$42.9M 0.5%
72,633
-25,695
-26% -$14.8M
HALO icon
66
Halozyme
HALO
$9.14B
$40.8M 0.47%
1,024,200
-43,300
-4% -$1.54M
BIO icon
67
Bio-Rad Laboratories Class A
BIO
$8.08B
$40.6M 0.47%
72,009
+32,326
+81% +$19.5M
ATRC icon
68
AtriCure
ATRC
$1.76B
$39.3M 0.46%
598,605
+100,049
+20% +$6.48M
MTEM
69
DELISTED
Molecular Templates, Inc.
MTEM
$38.2M 0.44%
738,534
+13,334
+2% +$589K
BAX icon
70
Baxter International
BAX
$11.4B
$38M 0.44%
489,880
+40,031
+9% +$3.35M
IQV icon
71
IQVIA
IQV
$34B
$36.8M 0.43%
159,120
-4,400
-3% -$1.04M
HZNP
72
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$36.3M 0.42%
345,100
-23,500
-6% -$2.29M
CRL icon
73
Charles River Laboratories
CRL
$10.6B
$35.9M 0.42%
126,406
+60,495
+92% +$18.7M
COO icon
74
Cooper Companies
COO
$14B
$34.8M 0.4%
332,864
-412
-0.1% -$41.5K
TFX icon
75
Teleflex
TFX
$5.93B
$34.7M 0.4%
97,714
-57
-0.1% -$18.8K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2022 Portfolio in Review

As of Q1 2022, Bellevue Group held 207 positions worth $8.61B, down 11% from $9.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bellevue Group withdrew a net $352M in Q1 2022, closing 30 positions and reducing 80 holdings. Its most notable exit was VOCERA COMMUNICATIONS, INC., an estimated $75.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Aurinia Pharmaceuticals worth $29.8M.

  • Bellevue Group's largest Q1 2022 buy was Aurinia Pharmaceuticals: 2,405,825 shares worth $29.8M.
  • Bellevue Group added most to Outset Medical in Q1 2022, an estimated $58.4M increase.
  • Bellevue Group's biggest Q1 2022 reduction was Biogen, cutting an estimated $109M.
  • Bellevue Group fully exited VOCERA COMMUNICATIONS, INC. in Q1 2022, selling an estimated $75.3M.
  • Bellevue Group's ten largest holdings make up 31% of its $8.61B portfolio in Q1 2022.
  • Bellevue Group opened 16 new positions and closed 30 in Q1 2022.
  • Bellevue Group's portfolio value fell 11% quarter-over-quarter to $8.61B.

Based on Bellevue Group's 13F filing for Q1 2022, filed 13 May 2022.